Valneva SE (NASDAQ:VALN - Get Free Report) saw unusually-strong trading volume on Wednesday . Approximately 53,386 shares were traded during mid-day trading, a decline of 4% from the previous session's volume of 55,813 shares.The stock last traded at $7.96 and had previously closed at $7.83.
Separately, HC Wainwright reissued a "buy" rating and set a $18.00 price objective on shares of Valneva in a research note on Friday, January 31st.
Check Out Our Latest Report on Valneva
The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The stock has a market cap of $681.61 million, a price-to-earnings ratio of -64.38 and a beta of 1.98. The firm's 50-day moving average is $4.71 and its 200 day moving average is $5.64.
A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC grew its position in Valneva SE (NASDAQ:VALN - Free Report) by 33.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 118,000 shares of the company's stock after purchasing an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned approximately 0.15% of Valneva worth $717,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 11.39% of the company's stock.
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.